|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM292677952 |
| 003 |
DE-627 |
| 005 |
20231225073637.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2019 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2019.01.004
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0975.xml
|
| 035 |
|
|
|a (DE-627)NLM292677952
|
| 035 |
|
|
|a (NLM)30639657
|
| 035 |
|
|
|a (PII)S1521-6616(18)30629-6
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Larionova, Regina V
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a In seroconverted rheumatoid arthritis patients a multi-reactive anti-herpes IgM profile is associated with disease activity
|
| 264 |
|
1 |
|c 2019
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 31.12.2019
|
| 500 |
|
|
|a Date Revised 31.12.2019
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2019 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Conflicting results have been reported regarding human herpes virus (HHV) reactivation in patients with rheumatoid arthritis (RA). To explore this link, 74 RA patients were selected and compared to 42 first degree relatives (FDR) from probands with RA and 25 healthy controls from the Tatarstan women cohort. The serological analysis was done by testing anti-HSV/CMV/EBV IgM, IgG, plus the IgG avidity index, and completed by evaluating HSV/CMV/EBV DNA by PCR. Results from these analyses reveal: (i) a long lasting infection of HHV in RA, FDR and healthy controls (IgG seroconversion >97%); (ii) an elevated IgM anti-HHV response in seroconverted RA patients which is related to HSV1/2 reactivation (HSV1/2 PCR+); and (iii) a multi-reactive IgM HHV burden profile associated with disease activity (DAS28). In conclusion, HSV1/2 reactivation in seroconverted RA patients is associated with an abnormal anti-HHV immune response, which was reflected in IgM HHV burden, and in activity disease profile
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a CMV
|
| 650 |
|
4 |
|a Disease activity
|
| 650 |
|
4 |
|a EBV
|
| 650 |
|
4 |
|a HSV
|
| 650 |
|
4 |
|a Reactivation
|
| 650 |
|
4 |
|a Rheumatoid arthritis
|
| 650 |
|
7 |
|a Antibodies, Viral
|2 NLM
|
| 650 |
|
7 |
|a Antirheumatic Agents
|2 NLM
|
| 650 |
|
7 |
|a DNA, Viral
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin G
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin M
|2 NLM
|
| 700 |
1 |
|
|a Arleevskaya, Marina I
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kravtsova, Olga A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Validov, Shamil
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Renaudineau, Yves
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 200(2019) vom: 15. März, Seite 19-23
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:200
|g year:2019
|g day:15
|g month:03
|g pages:19-23
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2019.01.004
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 200
|j 2019
|b 15
|c 03
|h 19-23
|